Nippon Shinyaku Co Ltd
TSE:4516
Nippon Shinyaku Co Ltd
Net Income (Common)
Nippon Shinyaku Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nippon Shinyaku Co Ltd
TSE:4516
|
Net Income (Common)
¥30.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Net Income (Common)
¥208.1B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
73%
|
CAGR 10-Years
15%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Net Income (Common)
¥245.8B
|
CAGR 3-Years
38%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Net Income (Common)
¥343.1B
|
CAGR 3-Years
40%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Net Income (Common)
¥387.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Net Income (Common)
-¥57.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nippon Shinyaku Co Ltd
Glance View
Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.
See Also
What is Nippon Shinyaku Co Ltd's Net Income (Common)?
Net Income (Common)
30.4B
JPY
Based on the financial report for Dec 31, 2024, Nippon Shinyaku Co Ltd's Net Income (Common) amounts to 30.4B JPY.
What is Nippon Shinyaku Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
17%
Over the last year, the Net Income (Common) growth was 26%. The average annual Net Income (Common) growth rates for Nippon Shinyaku Co Ltd have been -11% over the past three years , 14% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet